First clinical trial to recognize the needs of severely disabled MS patients

June 14, 2018, Queen Mary, University of London

A new clinical trial testing a disease-modifying drug for multiple sclerosis (MS) will be the first in the world to recognise the importance of wheelchair users retaining the use of their hands.

The team from Queen Mary University of London, Barts Health NHS Trust and pharmaceutical company Roche, hope that the study will make lasting changes in a field that has previously only looked at a patient's walking ability when assessing the potential of MS drugs.

MS is a degenerative disease of the central nervous system affecting approximately 120,000 people in the UK and 700,000 people in Europe, of which around 96,000 have the highly disabling primary progressive form.

Until now, clinical trials involving people with MS have focused on whether or not the drugs being tested preserve the ability to walk, rather than preserve the use of their hands. For example, if the person relies on a wheelchair, they have been excluded from participating in trials in the past.

Additionally, the NHS in the UK stops treatment with disease-modifying therapies for people who lose lower limb function and rely on a wheelchair, and the European Medicines Agency has also been an obstacle to those patients from participating in this type of research in the past. This is despite growing evidence that continuing treatment may delay worsening of their hand and arm function, which could dramatically improve quality of life.

Lead researcher Professor Gavin Giovannoni from Queen Mary University of London and Barts Health NHS Trust said: "Addressing the needs of people with progressive MS, who are typically more advanced in their disease course, is one of the major frontiers in MS research. Around a third of people living with progressive MS may already be confined to a wheelchair, so maintaining hand and is essential for them to stay independent and lead active lives."

The new international study, starting by the end of 2018, will evaluate the long-term safety and efficacy of the drug ocrelizumab by enrolling approximately 1,000 people with primary progressive MS across multiple countries. This will include people with more advanced disability, and those who need a wheelchair, where use of hands and arms is critical.

For the first time ever, the Nine-Hole Peg Test—a measure of arm, wrist and hand function—will be used as the main outcome to be measured in the trial. In the test, participants take pegs from a container, and one by one, place them into nine holes on a board, as quickly as possible. They then remove the pegs from the holes, one by one, and replace them back into the container.

By comparing how well patients who are given the drug ocrelizumab perform in this test, to those patients who are given a placebo, the team hope to be able to assess whether ocrelizumab may offer hope to patients by allowing them to retain their upper limb function.

Patrick Burke, a patient with advanced MS said: "The ability to use my hands and arms is now very important for a multitude of reasons. Without them I could not use a rollator, walker or mobility scooter."

Professor Giovannoni added: "For a number of years, through our #ThinkHand campaign, we have been urging industry to conduct a study looking at upper limb function in people with advanced MS. We're pleased that in collaboration with Roche, we will conduct a clinical trial that uses as a primary outcome for the first time."

Explore further: Primary progressive and relapsing remitting multiple sclerosis treated with ocrelizumab

Related Stories

Primary progressive and relapsing remitting multiple sclerosis treated with ocrelizumab

October 21, 2015
Three phase three clinical studies using the drug ocrelizumab to treat patients with multiple sclerosis (MS) have yielded positive results for treating two forms of the disease and the first ever positive results for a treatment ...

Genentech announces favorable results for MS drug ocrelizumab

October 9, 2015
Swiss pharmaceutical company Genentech a member of the Roche Group, has released (at the European Committee for Treatment and Research in Multiple Sclerosis meeting) findings from Phase III clinical trials for its multiple ...

Guidelines developed for use of drugs in multiple sclerosis

April 24, 2018
(HealthDay)—Guidelines have been developed for use of disease-modifying therapies (DMTs) in multiple sclerosis (MS), integrating findings from a systematic review. The review and guidelines were published online April 23 ...

Biomarkers and efficacy of vaccine responses among patients treated with new MS drug

April 26, 2018
In March 2017, the U.S. Food and Drug Administration approved ocrelizumab as the first treatment for both relapsing (RMS) and progressive forms of multiple sclerosis (MS), a genetic disease that afflicts approximately 400,000 ...

Surgery involving ultrasound energy found to treat high blood pressure

May 23, 2018
An operation that targets the nerves connected to the kidney has been found to significantly reduce blood pressure in patients with hypertension, according to the results of a clinical trial led in the UK by Queen Mary University ...

Cell therapy improves heart function, upper limb strength in Duchenne muscular dystrophy

November 15, 2017
After boys and young men with Duchenne muscular dystrophy received cardiac progenitor cell infusions, medical tests indicated that the patients' hearts appeared improved, results from a new study show. Patients in the study ...

Recommended for you

Classifying brain microglia: Which are good and which are bad?

December 6, 2018
Microglia are known to be important to brain function. The immune cells have been found to protect the brain from injury and infection and are critical during brain development, helping circuits wire properly. They also seem ...

Friend or foe? Brain area that controls social memory also triggers aggression

December 5, 2018
Columbia scientists have identified a brain region that helps tell an animal when to attack an intruder and when to accept it into its home. This brain area, called CA2, is part of the hippocampus, a larger brain structure ...

How the brain hears and fears

December 5, 2018
How is it that a sound can send a chill down your spine? By observing individual brain cells of mice, scientists at Cold Spring Harbor Laboratory (CSHL) are understanding how a sound can incite fear.

Adding new channels to the brain remote control

December 5, 2018
By enabling super-fast remote control of specific cells, light-activated proteins allow researchers to study the function of individual neurons within a large network—even an entire brain. Now one of the pioneers of 'optogenetics' ...

Microbial-based treatment reverses autism spectrum social deficits in mouse models

December 4, 2018
An unconventional approach has successfully reversed deficits in social behaviors associated with autism spectrum disorders (ASD) in genetic, environmental and idiopathic mouse models of the condition. Researchers at Baylor ...

'Error neurons' play role in how brain processes mistakes

December 4, 2018
New research from Cedars-Sinai has identified neurons that play a role in how people recognize errors they make, a discovery that may have implications for the treatment of conditions including obsessive-compulsive disorder ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.